Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Correlates of 5-year decline in 6-min walk distance in the COPDGene cohort

Boriek AM, Gordon J, Gwon Y, Adami A, Porszasz J, Rossiter HB, Rambod M, Chandra D, Diaz AA, Kinney GL, Make BJ, McDonald MN, Regan[...]

Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid Leukemia

Cai J, Yue C, Tomassetti S. Abnormal Eosinophils With Large, Distinctly Basophilic Granules (Harlequin Cells) on Peripheral Blood Smear: A Clue for Diagnosing Chronic Myeloid[...]

Hyperlactatemia and pulmonary gas exchange at rest and during exercise: lessons from patients on metformin

Haouzi P, Stringer WW, Mccully J, Pichurko BM. Hyperlactatemia and pulmonary gas exchange at rest and during exercise: lessons from patients on metformin. Eur J[...]